MI-DSPACE
19.12.2023 14:07:34 CET | Business Wire | Press release
At CES 2024, dSPACE will show how electric and self-driving cars can get on the road faster with innovative development, simulation, and validation solutions. As the exclusive on-vehicle computer technology sponsor of the Indy Autonomous Challenge (IAC), dSPACE will demonstrate how dSPACE solutions work in demanding racing environments at the Autonomous Challenge @ CES 2024 night race at the Las Vegas Motor Speedway. Eight solutions will be presented at the dSPACE booth no. 4300 in the LVCC, West Hall. Here are some highlights:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231219166904/en/
At the Autonomous Challenge @ CES 2024, which will be held on January 11 at the Las Vegas Motor Speedway, nine teams comprised of 17 universities will compete against each other with fully autonomous racecars. Photo Credits: Indy Autonomous Challenge
E-mobility: Testing of battery management systems, power electronics, and technologies for intelligent charging
Battery management systems (BMS) are crucial for the smooth operation of lithium-ion batteries, and ensure the efficient use of available capacity, optimum temperatures, avoid overcharging as well as deep discharges, and thereby ensure safe operation and long life of the energy storage systems. dSPACE demonstrates a modular system design for the testing of battery management systems (BMS) that enables the testing of modern BMS. The system's field of application in the areas of development and validation range from battery systems for electric cars and planes to energy storage systems for modern power grids.
Power HIL systems from dSPACE are the first choice where inverters, including control and power electronics, have to be tested at full power. Designed specifically for hardware-in-the-loop (HIL) simulation at power level, they combine the flexibility of established HIL systems with full performance, enabling exceptionally precise testing of power electronics. The tests go well beyond endurance and also include testing the control behavior with different dynamic operating points of e-motors.
The Smart Charging Solution is a complete solution for the development and testing of intelligent charging technologies. The solution takes international standards into account, ensures interoperability analyses and tests, and supports developers of onboard chargers, charging stations, and, in future, inductive charging systems, robot charging, and megawatt charging for the truck and aviation sector with a comprehensive range of test options and dynamic models.
Autonomous driving: High-precision tests in the virtual world
The development of functions for highly automated and autonomous driving places increasingly strict requirements on the quality and safety of functions. Virtual tests are frontloaded to earlier development phases and executed by internationally distributed development teams. To meet these requirements, dSPACE has developed solutions such as SIMPHERA, the web-based, highly scalable cloud solution for simulation and virtual validation, and the AURELION sensor simulation. At CES, dSPACE will demonstrate how logical scenarios generated from measurement data can then be used for scenario-based testing in SIMPHERA. In this way, real recorded scenarios can later be used for virtual validation. In addition, it is shown how AURELION achieves a very high degree of realism in the simulation – by comparing the synthetic sensor simulation with the real recorded measurement data of the same scenario.
In a joint demonstration with AWS, dSPACE presents an intelligent fleet and data management environment that enables targeted data collection campaigns for the development and validation of ADAS/AD algorithms. The solution aims to drastically shorten the lead time for data acquisition from the definition of requirements to the availability of the recorded vehicle and sensor data in the data center, thereby increasing the efficiency of the data-driven development process.
The simulation of software stacks on high-performance computers (HPCs) in the newest E/E architectures for software-defined vehicles (SDVs) presents a particular challenge in software integration testing. In order to efficiently validate such systems, cloud-based software-in-the-loop environments are required that enable the simulation of the software components on HPCs based on real ARM processors together with those of the rest of the E/E architecture. To this end, dSPACE is working with AWS to offer an end-to-end solution based on dSPACE VEOS and AWS Graviton.
IAC: dSPACE technology during night racing and at the exhibition stand
At the Autonomous Challenge @ CES 2024, which will be held on January 11 at the Las Vegas Motor Speedway, nine teams comprised of 17 universities will compete against each other with fully autonomous racecars. CES visitors are invited to experience the action on the Las Vegas Motor Speedway. In addition, dSPACE is presenting its technologies for the IAC at booth 5901 in the exhibition area of the Las Vegas Convention Center (LVCC) West. A proven dSPACE component in the vehicles is the AUTERA AutoBox, the central onboard computer that manages all sensor data and performs the complex trajectory calculations. The IAC schedule for 2024 and other innovations will be presented on Monday, January 8, as part of the IAC press conference.
About dSPACE
dSPACE is a leading provider of simulation and validation solutions worldwide for developing networked, autonomous, and electrically powered vehicles. The company's range of end-to-end solutions are used particularly by automotive manufacturers and their suppliers to test the software and hardware components in their new vehicles long before a new model is allowed on the road. Not only is dSPACE a sought-after partner in vehicle development, engineers also rely on our know-how at dSPACE when it comes to aerospace and industrial automation. Our portfolio ranges from end-to-end solutions for simulation and validation to engineering and consulting services as well as training and support. With more than 2,500 employees worldwide, dSPACE is headquartered in Paderborn, Germany; has three project centers in Germany; and serves customers through its regional companies in the USA, the UK, France, Japan, China, Croatia, Korea, and India.
About the IAC
The Indy Autonomous Challenge (IAC) organizes racing competitions among university affiliated teams representing 17 universities from around the world to program fully autonomous racecars and compete in a series of history-making events at iconic tracks. Based in Indiana, the IAC is working to establish a hub for performance automation in the state and is harnessing the power of innovative competitions to attract the best and the brightest minds from around the globe to further state-of-the-art technology in safety and performance of automated vehicles. The IAC started as a $1 million prize competition with 31 university teams signing up to compete more than three years ago, representing top engineering and technology programs from 15 U.S. states and 11 countries. Follow the IAC @IndyAChallenge on LinkedIn, Twitter, Instagram, Facebook, & YouTube.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231219166904/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom